Ethnoracial inclusion in clinical trials of psychedelics: a systematic review.
EClinicalMedicine August 1, 2024 Marcus Hughes, Albert Garcia‐romeu 42 citations
A systematic review of 39 studies published between 1994 and 2024 found that ethnoracial diversity remains low in clinical psychedelic research. Among all included studies (n=1393), 85.0% of participants identified as non-Hispanic White, 2.9% as Black, 5.9% as Latinx/Hispanic, 3.2% as Asian, 1.9% as Indigenous, and 3.7% as mixed race. In studies conducted in the USA (n=1074), 84.5% were White, 3.4% Black, 7.4% Latinx/Hispanic, 4.0% Asian, 1.4% Indigenous, and 3.7% mixed race. The proportion of White to non-White participants decreased in US studies after 2017, indicating some progress, but minoritized groups remain underrepresented.